Drug Discovery Featured Articles & Applications

  1. Radiopharmaceuticals: Navigating FDA Guidance And CMC Considerations 6/2/2025

    The unique nature of radiopharmaceuticals necessitates specialized regulatory considerations, particularly for chemistry, manufacturing, and controls (CMC).

  2. Designing Our Way Toward Circular RNA Medicines With AI 5/21/2025

    The closed-loop structure of circular RNA can offer sustained, durable expression. We caught up with Sail Biomedicines' Kerry Benenato and Rajesh Ramaswamy to chat about ways to leverage AI for design/engineering.

  3. Will Genome Modifications Define Next-Gen AAV Vectors? 5/20/2025

    AAV vectors composed of naturally occurring capsids are suboptimal. Gentle genetic alterations hold promise for safer, more efficient therapy.

  4. Formulation Is Key For Y-mAbs' Self-Assembling Antibody 5/16/2025

    The radiotherapy company's novel SADA construct uses self-assembling tetramers to deliver isotopes directly to cancer cells for a highly targeted, less toxic treatment.

  5. ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy 5/12/2025

    Despite their potential to revolutionize treatment paradigms, antibody-drug conjugates (ADCs) face challenges that companies must tackle for successful development.

  6. Protecting Intellectual Property In The Genomics Revolution 5/9/2025

    Providing superior IP protection for genomics-related inventions already requires — and will require in the future — a more nuanced strategy combining patents, trade secrets, and copyrights.

  7. PheWAS Is Your Friend 5/7/2025

    Discovery and preclinical development expert Stephen Pinkosky, MD, Ph.D. explores the resurgence and growing impact of PheWAS and multi-omics in drug development.

  8. Understanding The Impact Of An RMP On Patient Risks Using Relational Risk Analysis 5/5/2025

    Using relational risk analysis, let's take a closer look at risk management plans for identifying and managing adverse reactions for administering a new therapy to a patient.

  9. Designing The Next Wave Of T Cell Engagers 5/1/2025

    Abpro's associate director of biology has led programs in immuno-oncology R&D with a focus on therapeutic T cell engagers. We caught up with him to discuss how industry can pave a future for the field.

  10. AI Vs. Humans In Novel Drug Target Identification 4/30/2025

    Artificial intelligence is beginning to replace humans in drug discovery, one expert warns — but the industry isn’t ready for the shift.